PD-1 Protein, Human (CHO, Fc)

PD-1 Protein is an important immune regulatory molecule expressed on the surface of activated immune cells. By binding to its ligands (PD-L1/PD-L2), the PD-1 Protein exerts immunosuppressive effects. PD-1 Protein can be used in the research of tumors, autoimmune diseases, and other conditions. PD-1 protein, Human (CHO, Fc) is a recombinant PD-1 protein expressed by CHO cells and carries a C-hFc tag^[1][2].

PD-1, also known as CD279, is a 55 kDa transmembrane protein consisting of 288 amino acids, including a signal peptide, extracellular domain, transmembrane domain, and intracellular domain. As an immune checkpoint molecule, PD-1 is mainly expressed on the surface of activated immune cells such as T cells and B cells. Notably, PD-1 is highly expressed on tumor-specific T cells. PD-1 acts as an inhibitor of adaptive and innate immune responses. Under normal conditions, PD-1 maintains immune tolerance by binding to its ligands PD-L1/PD-L2 to avoid autoimmune damage. However, when PD-1 binds to PD-L1/PD-L2 on tumor cells, it leads to T cell functional exhaustion, inhibits cytokine secretion, and facilitates tumor immune escape. Currently, PD-1 serves as a core target for cancer immunotherapy, and its inhibitors can restore the tumor-killing ability of T cells by blocking this binding^[1][2].

Momordin Ic (HY-N0330) can block the binding of PD-1 (Human) to PD-L1^[3].

1.1 µg/mL (100 µL/well) of immoblized human PD-L1-Fc can bind human Biotin-PD-1-Fc and the ED₅₀ is <25 μg/mL.
2.Measured by its binding ability in a functional ELISA. When Recombinant Human PD-1 (HY-P73361) is present at 0.1 μg/mL, can bind biotinylated Recombinant Human PD-L1. The ED₅₀ for this effect is 0.3479 μg/mL.

• 
  Measured by its binding ability in a functional ELISA. When Recombinant Human PD-1 (HY-P73361) is present at 0.1 μg/mL, can bind Recombinant Human PD-L1. The ED₅₀ for this effect is 0.3479 μg/mL.
• 
  PD-1 Protein, Human (CHO, Fc) captured on CM5 Chip can bind PD-L1 Protein, Human (HY-P7398) with an affinity constant of 1.86E-7 M as determined in SPR assay (Biacore 8K).

Human

CHO

C-hFc

Q15116 (L25-Q167)

5133  [NCBI]

Extracellular Domain

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ

Approximately 50-76 kDa due to the glycosylation.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

1.Lyophilized from a 0.22 μm filtered solution of PBS.
2.Lyophilized from a 0.22 μm filtered solution of PBS, pH 8.0, 8% trehalose.
Please refer to the lot-specific COA for specific buffer information.

<0.2 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. /biology-dictionary/baf3-cell.html  [Content Brief]

  [2]. Syn NL, et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017 Dec;18(12):e731-e741.  [Content Brief]

  [3]. Han Y, et al. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020 Mar 1;10(3):727-742.  [Content Brief]

  [4]. Wu S, et al. Discovery of Momordin Ic that selectively reduces PD-L1 expression in multiple myeloma cells by recruiting SYVN1. Food Bioscience, 2024, 61: 104732.